Celestia Higano

Celestia Higano is a prostate cancer specialist who has contributed to the development of enzalutamide in mHSPC and other hormonal therapy investigations. She has been a co-investigator in multiple phase III trials transforming mHSPC management and has expertise in managing treatment-related morbidity including bone health consequences of long-term ADT. Her advocacy work focuses on patient education and support for men with advanced prostate cancer. Higano has served on NCCN and ASCO guideline committees for prostate cancer.